her compounded semaglutide Tirzepatide Compounded' weight-loss drugs are a

This is problematic because: Imprecise measurements: 1 ml on a 10 ml syringe is difficult to measure accurately

The finding was replicated by tirzepatide maker Eli Lilly, who carried out tests on the impact of mixing tirzepatide and B12 and released a statement underscoring that the clinical consequences of the new molecule are not known

found that fast escalation to 8 mg produced GI adverse events in 50% of participants, compared to roughly 35% with gradual titration (Rosenstock et al., Lancet, 2023)

Red flags requiring urgent medical attention include triglyceride levels 10 mmol/L (risk of pancreatitis) and suspected familial hypercholesterolaemia, which requires specialist referral